Qiagen (QGEN) versus Its Peers Head to Head Survey

Share on StockTwits

Qiagen (NYSE: QGEN) is one of 94 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Qiagen to related companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.

Insider & Institutional Ownership

62.0% of Qiagen shares are owned by institutional investors. Comparatively, 49.5% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 17.3% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Qiagen and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Qiagen $1.42 billion $40.39 million 28.87
Qiagen Competitors $1.02 billion $91.59 million -2.42

Qiagen has higher revenue, but lower earnings than its rivals. Qiagen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Qiagen and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen 0 3 4 0 2.57
Qiagen Competitors 520 1840 4770 176 2.63

Qiagen currently has a consensus price target of $38.50, suggesting a potential upside of 5.02%. As a group, “Biological products, except diagnostic” companies have a potential upside of 14.43%. Given Qiagen’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Qiagen has less favorable growth aspects than its rivals.

Volatility and Risk

Qiagen has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Qiagen’s rivals have a beta of 1.67, indicating that their average share price is 67% more volatile than the S&P 500.


This table compares Qiagen and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Qiagen 3.79% 11.91% 6.13%
Qiagen Competitors -6,095.52% -68.89% -26.13%


Qiagen rivals beat Qiagen on 7 of the 13 factors compared.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply